HPV DNA 12 High-risk type detection & genotyping

Identified More than 120 different types of HPV And about one-third of them can infect genital epithelial cells. They can be classified as follows:

• Group 1 (carcinogenic types for humans) - HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58 and HPV59
• Group 2A (most likely to be carcinogenic to humans) - HPV68
• Group 2B (most likely to be carcinogenic to humans) - HPV26, HPV30, HPV34, HPV53, HPV66, HPV67, HPV 69, HPV70, HPV73, HPV82, HPV85 and HPV97.

between them HPV16 is the most carcinogenic type, which causes 50-60% of cervical cancers while HPV18 Participates in about 10-12% of cases. Thus, 96% of all cases of cervical cancer belong to one of 13 types of HPV (groups 1 and 2A).

Persistence of the virus for 1 year or 2 years, especially HPV16, results in CIN3 (carcinoma-in-situ) - abnormal cells are found in the entire thickness of the cervical surface layer, although the process is not widespread in the deeper layers) or more advanced 3-20% risk of developing lesions (CIN30 +); Untreated CIN3 has a 30% chance of causing invasive cervical cancer within 30 years, while only 3% of untreated CIN1 can become invasive.

Cervical cancer screening The primary goal is to prevent cancer morbidity and mortality. The optimal screening strategy is to identify pre-existing lesions that may progress to invasive cancer and at the same time prevent transient HPV infections.

HPV (human papillomavirus) Screening test, Detects 12 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 - types with individual genotyping. The test is based on the determination of HPV DNA by real-time PCR (PCR) research method. 

Genotyping of HPV infection allows:

• Stratification of high-risk patients (HPV 16, 18 or other high-risk HPV types);
• Detection of multi-infections;
• Specifying the need for re-treatment due to infection with the same or a new type of HPV;
• Monitoring the effect after receiving the HPV vaccine;
• Determine the specific outcome of cytological examination of cervical lesions (e.g. HPV18 and adenocarcinoma).

How to prepare HPV For a DNA test?

Before smearing:

• Do not use a vaginal shower;
• It is recommended to abstain from sexual intercourse for at least 24-48 hours;
• Do not urinate directly before smearing;
• Contraceptive use should be discontinued three days in advance;
• The smear is taken 24-48 hours after the colposcopy and 24 hours after the vaginal ultrasound examination;
• Perform external genital hygiene procedures without the use of soap and other detergents;
• The test may be performed no earlier than 10-14 days after completion of antibacterial, antifungal, or topical antiseptics;
• It is recommended to perform the test during ovulation or in the presence of symptoms of inflammatory disease of the urogenital tract.
• No examination is performed during menstrual bleeding.
• The study is conducted 2 weeks after taking preparations containing microorganisms (probiotics, eubiotoc).

Research material

Recommended for PCR diagnostics:

• Consumption of the first part of urine in women has a lower diagnostic sensitivity (about 80-90%) than in men, so in the case of womenUrogenital smear Recognized as the most optimal material for testing. The study of the first part of the urine in women can be used in situations where it is difficult to take a smear from the vagina and cervix (for example, in pregnant women) or in the face of a cystitis clinic (including chronic). It is the most optimal time to examine women last Menstruation first from the day fourth Sunday.

• You can pick up a smear brush and Eppendorf with transport fluid at Synevo branches.
• To take a smear, contact a doctor-specialist (urologist, gynecologist).

In women: Cells from exocervical, endocervical, and transitional regions (transformation zone) are required for the study. The study material should be taken by a professional.

in men:  cells of the urethral mucosa.

Research Material in the laboratory Should bring 13:00 p.m-till.